EndoGastric funds US sales with $30m round:
This article was originally published in Clinica
Natural orifice surgery (NOS) specialist EndoGastric Solutions has completed a $30m series D round of financing. Redmond, Washington-based EndoGastric plans to use the new finances to expand sales and marketing efforts for its transoral StomaphyX device for binding tissue in the gastrointestinal tract to help weight loss, and fund the launch of its EsophyX device for treating gastroesophageal reflex disease later this year. The round was lead by DeNovo Ventures and included contributions from existing investors Chicago Growth Partners, MPM Capital, Advanced Technology Ventures, Foundation Medical Partners and Oakwood Medical Investors. The financing sees DeNovo's Joe Mandato join the EndoGastric board of directors.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.